Rozovsky Katia, Koplewitz Benjamin Z, Krausz Yodphat, Revel-Vilk Shoshana, Weintraub Michael, Chisin Roland, Klein Martine
Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
AJR Am J Roentgenol. 2008 Apr;190(4):1085-90. doi: 10.2214/AJR.07.2107.
In pheochromocytoma and neuroblastoma, pathologic findings on metaiodobenzylguanidine (MIBG) scintigraphy (planar and SPECT) and on diagnostic CT are sometimes difficult to correlate. Furthermore, CT reading may be impaired by anatomic distortion after surgery or irradiation and if contrast agent is not injected. The present study evaluates the impact of SPECT/CT fusion images on correlation and image analysis of both techniques.
Eleven patients, three adults (age range, 27-64 years) with pheochromocytoma and eight children (age range, 16-72 months) with neuroblastoma, underwent 15 (123)I-MIBG scintigraphy (whole body and SPECT/CT) and diagnostic CT during follow-up after treatment, with a time interval of 2 to 30 days (mean, 12 days) between MIBG scintigraphy and diagnostic CT. The diagnostic CT scans were read twice: blindly and with knowledge of the SPECT/CT findings. The scintigraphic and anatomic data were subsequently compared and were verified by clinical outcome.
Of 15 imaging studies, there were nine cases of discordance between SPECT/CT and diagnostic CT, whereas concordant findings of planar MIBG and diagnostic CT were observed in six studies. Overall, SPECT/CT provided additional information in eight of the 15 cases (53%) and in eight of nine discordant studies (89%). In one case of pheochromocytoma in which anatomy was distorted by previous surgery and contrast agent was not injected, SPECT/CT findings guided the diagnostic CT that had initially misinterpreted the right adrenal gland as the inferior vena cava. In three of 11 studies performed for neuroblastoma, SPECT/CT facilitated the diagnostic CT reading: in one study, a small paravertebral thickening was overlooked at blind CT reading and in another case, SPECT/CT localized and characterized a soft-tissue mass medial to the iliac bone, which was missed on diagnostic CT in an area of difficult differential anatomy (bowel loops and eventual involved lymph nodes). In the third case, SPECT/CT directed the diagnostic CT to the MIBG abnormality after multiple surgical procedures. In these four cases, MIBG SPECT/CT allowed for localization of the pathologic site that was difficult to visualize on diagnostic CT. In four additional neuroblastoma studies in which a residual mass was present on diagnostic CT, planar MIBG scintigraphy was negative. SPECT/CT, focused on the area of the diagnostic CT abnormality, showed no focal MIBG uptake, thus increasing the diagnostic certainty of remission.
In cases of equivocal diagnostic CT, SPECT/CT bridges the gap between MIBG scintigraphy and diagnostic CT, with guidance of the diagnostic CT and characterization of its findings. In this small series, MIBG SPECT/CT increased the diagnostic certainty in 89% of discordant studies.
在嗜铬细胞瘤和神经母细胞瘤中,间碘苄胍(MIBG)闪烁扫描(平面和SPECT)的病理结果与诊断性CT的结果有时难以相互关联。此外,手术后或放疗后的解剖结构变形以及未注射造影剂时,CT判读可能会受到影响。本研究评估SPECT/CT融合图像对这两种技术的相关性及图像分析的影响。
11例患者,3例成年嗜铬细胞瘤患者(年龄范围27 - 64岁)和8例儿童神经母细胞瘤患者(年龄范围16 - 72个月),在治疗后的随访期间接受了15次(123)I - MIBG闪烁扫描(全身及SPECT/CT)和诊断性CT,MIBG闪烁扫描与诊断性CT之间的时间间隔为2至30天(平均12天)。诊断性CT扫描进行了两次判读:一次是盲法,另一次是在知晓SPECT/CT结果的情况下。随后对闪烁扫描和解剖学数据进行比较,并通过临床结果进行验证。
在15项影像学研究中,SPECT/CT与诊断性CT之间存在9例不一致情况,而在6项研究中观察到平面MIBG与诊断性CT结果一致。总体而言,SPECT/CT在15例中的8例(53%)以及9例不一致研究中的8例(89%)提供了额外信息。在1例因既往手术导致解剖结构变形且未注射造影剂的嗜铬细胞瘤病例中,SPECT/CT结果指导了最初将右肾上腺误判为下腔静脉的诊断性CT。在为神经母细胞瘤进行的11项研究中的3项中,SPECT/CT有助于诊断性CT的判读:在1项研究中,盲法CT判读时遗漏了一个小的椎旁增厚;在另一例中,SPECT/CT定位并明确了髂骨内侧的一个软组织肿块,该肿块在诊断性CT的一个解剖结构难以鉴别(肠袢和可能受累的淋巴结)的区域被遗漏。在第3例中,经过多次手术后,SPECT/CT引导诊断性CT发现了MIBG异常。在这4例中,MIBG SPECT/CT能够定位诊断性CT上难以显示的病理部位。在另外4项诊断性CT显示有残留肿块的神经母细胞瘤研究中,平面MIBG闪烁扫描为阴性。聚焦于诊断性CT异常区域的SPECT/CT未显示局灶性MIBG摄取,从而提高了缓解诊断的确定性。
在诊断性CT结果不明确的情况下,SPECT/CT弥合了MIBG闪烁扫描与诊断性CT之间的差距,对诊断性CT起到指导作用并明确其结果。在这个小样本系列中,MIBG SPECT/CT在89%的不一致研究中提高了诊断的确定性。